ChromaDex Corp. (CDXC) - Price-to-Projected Revenue Ratio

ChromaDex Corporation (CDXC) is a recognized authority in cellular rejuvenation due to its Niagen patents. The projected P/S metric helps assess the business valuation, with the indicator holding around 3.20. The company capitalizes on the demand for biohacking in the US and Asia by creating components for anti-aging cosmetics. Stable production line operations and planned capacity utilization guarantee uninterrupted product output.

CDXC ChromaDex: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 03/19/2025

ChromaDex - analytical breakdowns and key metrics (CDXC)

- market price and analyst price targets:

Price Chart ChromaDex Corporation|CDXC - Fair Value Consensus

- market capitalization indicators:

Market Value ChromaDex Corporation|CDXC - Total Enterprise Value

- book value of equity indicators:

Net Assets per Single Share ChromaDex|CDXC - Company Net Assets|Market Capitalization to Book Value Ratio chromadex.com|CDXC - Company Total Assets

- debt and liquidity data:

- business earnings and investment ratios data:

CDXC - Net Income|Expected Profit ChromaDex Corporation|CDXC - Market Cap to Earnings|Future Price to Earnings ChromaDex Corporation|CDXC - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ChromaDex|CDXC - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months ChromaDex|CDXC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months chromadex.com|CDXC - Earnings per share increase in current year|Earnings growth forecast for next year ChromaDex Corporation

- sales and revenue data:

CDXC - Revenue and Sales Volume|Company Future Sales Volume ChromaDex|CDXC - Market Cap to Sales Volume|Forward P/S Multiple ChromaDex Corp|CDXC - Annual Revenue Growth (Last Twelve Months)

Initial company analysis:ChromaDex Corp. (CDXC)

The optimization of agricultural raw material supply chains and the diversification of extractors at ChromaDex Corporation (CDXC) directly impact the stability of future revenue streams. By analyzing the forward P/S valuation metric on GURU.Markets, an investor can see the ratio of current market capitalization to projected sales, enabling a real-time assessment of the company's market value against current management guidance and the determination of the premium paid for expected growth.

Competitor analysis for ChromaDex Corporation

Price-to-Projected Revenue Ratio Mondelez International MDLZ|Forward Price to Sales HSY|Conagra Brands Inc - Forward P/S Multiple|OTLY: Price-to-Projected Revenue Ratio|DDC Enterprise Ltd (DDC) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Above Food Ingredients, Inc. (ABVE)|Price-to-Projected Revenue Ratio Paranovus Entertainment Technology Inc.|Forward P/S Multiple Natural Alternatives Corp|Price-to-Projected Revenue Ratio Chanson (CHSN)|MLEC (Moolec Science S.A.) - Forward Price to Sales